Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

Core Insights - Neurocrine Biosciences has initiated a Phase 2 clinical study for NBI-1065890, a selective VMAT2 inhibitor aimed at treating tardive dyskinesia (TD) [1][2] - The study will involve approximately 100 adult subjects and will evaluate the efficacy, safety, and tolerability of NBI-1065890 compared to a placebo, with the primary endpoint being the change in AIMS dyskinesia total score at Week 8 [2] Company Overview - Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders, with a history of successful drug development including valbenazine for TD [3][6] - The company has a robust pipeline with multiple compounds in mid- to late-phase clinical development, reflecting its commitment to addressing under-treated conditions [6] Tardive Dyskinesia (TD) Context - TD is a movement disorder characterized by uncontrolled and repetitive movements, often resulting from the use of certain antipsychotic medications, affecting an estimated 800,000 adults in the U.S. [4][5] - The condition can lead to significant disruption in patients' lives, highlighting the need for effective treatment options [4]